iCad Inc. got pre-market approval from the Food & Drug Administration for software it says will locate the best point to perform a needle biopsy of the breast.
The Nashua, N.H.-based computer-aided detection products maker said its PrecisionPoint product won 510(k) pre-market notification clearance from the federal watchdog agency March 31.
PrecisionPoint will be integrated into iCad’s CADvue breast MRI image review software.